{"entity":{"id":"nct04395508","kind":"trial","name":"At-home pertuzumab and trastuzumab expanded access","aka":["An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic"],"tldr":"This expanded-access program provided at-home injections of pertuzumab and trastuzumab to support continuity of care during the pandemic. It is not a randomized trial; the registry now marks the program approved for marketing.","summary":"This expanded-access program provided at-home injections of pertuzumab and trastuzumab to support continuity of care during the pandemic. It is not a randomized trial; the registry now marks the program approved for marketing.\n\nExpanded access study registered as NCT04395508, sponsored by Genentech, Inc.. No drug-development phase applies in the structured registry record. Registry status checked October 10, 2026: approved for marketing. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.","asOf":"2026-10-10","links":[{"label":"ClinicalTrials.gov NCT04395508","url":"https://clinicaltrials.gov/study/NCT04395508"},{"label":"UCSF study listing and local availability","url":"https://clinicaltrials.ucsf.edu/trial/NCT04395508"}],"tags":["ucsf-breast-coverage","expanded-access"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pertuzumab","trastuzumab"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04395508","phase":"not-applicable","setting":"Early or metastatic HER2-positive breast cancer during the COVID-19 pandemic","sponsor":"Genentech, Inc.","participation":[{"nct":"NCT04395508","source":"https://clinicaltrials.gov/study/NCT04395508","fetchedAt":"2026-10-10T20:54:22.910516Z","studySha256":"f19aafe257fd54019017805977d0bd72e339bee027047ef3895461d3ae718955","overallStatus":"APPROVED_FOR_MARKETING","lastUpdatePosted":"2022-07-05","leadSponsor":"Genentech, Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"siteCount":12,"recruitingSiteCount":0,"countries":["United States"]}],"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04395508/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}